← Back to Screener
Design Therapeutics, Inc. Common Stock (DSGN)
Price$12.51
Favorite Metrics
Price vs S&P 500 (26W)79.73%
Price vs S&P 500 (4W)17.96%
Market Capitalization$786.32M
All Metrics
Book Value / Share (Quarterly)$3.52
P/TBV (Annual)0.38x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.90
Price vs S&P 500 (YTD)33.28%
EPS (TTM)$-1.22
10-Day Avg Trading Volume0.33M
EPS Excl Extra (TTM)$-1.22
EPS (Annual)$-0.88
ROI (Annual)-20.65%
Cash / Share (Quarterly)$3.64
ROA (Last FY)-19.83%
EBITD / Share (TTM)$-1.25
ROE (5Y Avg)-19.54%
Cash Flow / Share (Annual)$-0.90
P/B Ratio3.70x
P/B Ratio (Quarterly)2.51x
Net Income / Employee (Annual)$-1
ROA (TTM)-31.08%
EPS Incl Extra (Annual)$-0.88
Current Ratio (Annual)17.14x
Quick Ratio (Quarterly)16.97x
3-Month Avg Trading Volume0.32M
52-Week Price Return292.31%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.09
P/S Ratio (Annual)3418.79x
Asset Turnover (Annual)0.01x
52-Week High$12.98
EPS Excl Extra (Annual)$-0.88
CapEx CAGR (5Y)19.26%
26-Week Price Return83.72%
Quick Ratio (Annual)16.97x
13-Week Price Return39.80%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)17.14x
Enterprise Value$769.466
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3600.00%
Cash / Share (Annual)$3.64
3-Month Return Std Dev53.53%
Net Income / Employee (TTM)$-1
ROE (Last FY)-20.65%
EPS Basic Excl Extra (Annual)$-0.88
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.22
ROI (TTM)-32.72%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.86
Price vs S&P 500 (52W)262.48%
Year-to-Date Return35.93%
5-Day Price Return2.08%
EPS Normalized (Annual)$-0.88
ROA (5Y Avg)-18.65%
Net Profit Margin (Annual)-3600.00%
Month-to-Date Return19.83%
Cash Flow / Share (TTM)$-1.28
EBITD / Share (Annual)$-0.87
Operating Margin (Annual)-3621.74%
ROI (5Y Avg)-19.54%
EPS Basic Excl Extra (TTM)$-1.22
P/TBV (Quarterly)0.44x
P/B Ratio (Annual)2.51x
Book Value / Share (Annual)$3.52
Price vs S&P 500 (13W)39.12%
Beta1.70x
Revenue / Share (TTM)$0.00
ROE (TTM)-32.72%
52-Week Low$2.88
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.09
4.09
4.33
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DSGNDesign Therapeutics, Inc. Common Stock | — | — | — | — | $12.51 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC molecules, a proprietary platform of small-molecule therapeutics designed to treat inherited diseases caused by nucleotide repeat expansions such as Friedreich Ataxia, Myotonic Dystrophy, Huntington's Disease, and Fuchs Endothelial Corneal Dystrophy. The company's GeneTAC candidates are designed to address the underlying genetic causes of these conditions, offering potential disease-modifying treatments for currently incurable genetic disorders.